1170150
doi
10.5281/zenodo.1170150
oai:zenodo.org:1170150
FORMULATION DEVELOPMENT AND INVITRO EVALUATION OF RANOLAZINE EXTENDED RELEASE TABLETS
Alladi saritha and Rebecca Sanjana
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
ranolazine, extended release tablets, Compritol, Carbopol934P
<p>The ranolazine extended release tablets can be prepared by wet granulation method using different polymers in varying combinations. Tablet blends were prepared and micromeritic studies were carried out for those blends and found to be within the limits. Compatability studies were carried out and found that drugs and excipients are compatible with each other. Post compression parameters were carried out found to be within the limits. Also dissolution data of all formulations reveals that as combination of Compritol, Carbopol934P increases the percentage drug release was found to be increased Formulation (F8) containing combination of Compritol, Carbopol934P shows that the 99.5% drug release was found in 24hrs and found similar with that of innovator. On comparing R2 with innovator, formulation (f8) shows similar results with marketed formulation Key words: ranolazine, extended release tablets, Compritol, Carbopol934P</p>
Zenodo
2018-02-09
info:eu-repo/semantics/article
1170149
1579540744.613883
842461
md5:19ec7b4609f09e9dbb2f8b26470fd21e
https://zenodo.org/records/1170150/files/92.saritha ranolazine.pdf
public
10.5281/zenodo.1170149
isVersionOf
doi
INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES
05
01
682-687
2018-02-09